KeyBanc Capital Markets downgraded Omnicell from Overweight to Sector Weight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/4/2026 | $70.00 | Neutral → Buy | BofA Securities |
| 1/8/2026 | $60.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 5/14/2025 | $35.00 | Equal Weight → Overweight | Wells Fargo |
| 10/31/2024 | $44.00 → $57.00 | Buy → Neutral | BofA Securities |
| 8/2/2024 | $26.00 → $39.00 | Underweight → Equal Weight | Barclays |
| 1/3/2024 | $33.00 | Underweight | Barclays |
| 11/3/2023 | $39.00 → $28.00 | Underweight → Equal Weight | Wells Fargo |
| 11/3/2023 | Buy → Neutral | BTIG Research |
SD - OMNICELL, INC. (0000926326) (Filer)
8-K - OMNICELL, INC. (0000926326) (Filer)
SCHEDULE 13G - OMNICELL, INC. (0000926326) (Subject)
Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, announced that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9, 2026, at 3:20 PM EDT. Live and archived webcasts of the presentation will be available through the Omnicell website at: https://ir.omnicell.com/events-and-presentations/ About Omnicell Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying
Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, announced that it will present at the BofA Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8:40 a.m. PDT. Live and archived webcasts of the presentation will be available through the Omnicell website at: https://ir.omnicell.com/events-and-presentations/ About Omnicell Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying automation and
Newly established role strengthens understanding of healthcare clinician needs to help shape the Company's innovation priorities and portfolio decisions Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Rick Couldry has joined the Company as Senior Vice President, Chief Pharmacy and Clinical Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429498071/en/Omnicell Welcomes Rick Couldry to the Newly-Created Role of SVP, Chief Pharmacy and Clinical Officer In this newly created position, Couldry
4 - OMNICELL, INC. (0000926326) (Issuer)
4 - OMNICELL, INC. (0000926326) (Issuer)
4 - OMNICELL, INC. (0000926326) (Issuer)
BofA Securities upgraded Omnicell from Neutral to Buy and set a new price target of $70.00
KeyBanc Capital Markets upgraded Omnicell from Sector Weight to Overweight and set a new price target of $60.00
Wells Fargo upgraded Omnicell from Equal Weight to Overweight and set a new price target of $35.00
4 - OMNICELL, INC. (0000926326) (Issuer)
Omnicell delivers strong first quarter 2026 financial results Raises full year 2026 non-GAAP EBITDA and non-GAAP EPS guidance Customer engagement underway for Omnicell Titan XT and OmniSphere Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today reported financial results for the first quarter ended March 31, 2026. First quarter results reflected strong execution across the business, supported by demand for Omnicell's connected device portfolio and solid performance across the Company's core points of care solutions. We believe that performance during the quarte
Omnicell, Inc. (NASDAQ:OMCL), a leading healthcare technology provider focused on empowering autonomous medication management, will release its financial results for the first quarter 2026, before market open on Tuesday, April 28, 2026. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 9381205. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/event
Omnicell delivers solid fourth quarter 2025 financial results Announces major step toward autonomous medication management with the launch of its next generation dispensing system, Titan XT, at the American Society of Health-System Pharmacists (ASHP) 2025 Midyear Clinical Meeting & Exhibition Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced results for its fiscal year and fourth quarter ended December 31, 2025. "We finished 2025 with solid fourth quarter financial results, delivering full year 2025 total revenues, product booking
Newly established role strengthens understanding of healthcare clinician needs to help shape the Company's innovation priorities and portfolio decisions Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leading healthcare technology provider focused on empowering autonomous medication management, today announced that Rick Couldry has joined the Company as Senior Vice President, Chief Pharmacy and Clinical Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429498071/en/Omnicell Welcomes Rick Couldry to the Newly-Created Role of SVP, Chief Pharmacy and Clinical Officer In this newly created position, Couldry
Seasoned leader brings more than 30 years of experience driving growth for healthcare and technology companies Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced the appointment of Baird Radford as Executive Vice President and Chief Financial Officer of the Company, effective August 26, 2025. Mr. Radford succeeds Nchacha Etta, who will be stepping down from the role, as announced earlier this year. Mr. Etta will remain with the Company in an advisory role through November 2025 to help ensure a smooth transition of responsibilities. This press release features multimedia. View the full release
The Company taps business and operations executive with expertise that spans healthcare and med tech to help scale pharmacy automation and drive multi-year innovation and excellence Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925324631/en/Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of Omnicell, effective October 7, 2024
SC 13G/A - OMNICELL, INC. (0000926326) (Subject)
SC 13G/A - OMNICELL, INC. (0000926326) (Subject)
SC 13G/A - OMNICELL, INC. (0000926326) (Subject)